NCT06494878RecruitingPhase 3
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 8805 (estimated)
- First submitted
- 12 Jun 2024
- Start date
- 4 Jun 2026
- Primary completion date
- Sept 2030
- Lead sponsor
- University of Calgary
- NCT number
- NCT06494878
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 8805
- From 4 Jun 2026 to the primary completion date, Sept 2030
- 12 sites in 7 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received more than 1 dose of LMWH since delivery
Other illness
- Need for postpartum LMWH prophylaxis or systemic anticoagulation as judged by their physician and/or local investigator. May include but is not limited to:
- Documented history of provoked or unprovoked VTE
- Mechanical heart valve(s)
- Known antiphospholipid syndrome (APS)
- Known high-risk inherited thrombophilia i) Antithrombin deficiency, or ii) Homozygous factor V Leiden, or iii) Homozygous prothrombin gene mutation, or iv) More than 1 thrombophilia: any combination of 2 or more: factor V Leiden, prothrombin gene mutation, protein C deficiency, protein S deficiency
- Need for postpartum ASA as judged by their physician and/or local investigator. May include but is not limited to:
- Documented history of myocardial infarction
- Documented history of ischemic stroke or transient ischemic attack (TIA)
- Active bleeding, excluding normal vaginal bleeding, at the time of randomization
- Known medical condition as judged by their physician and/or local investigator to be a contraindication to ASA or LMWH including known ASA or LMWH allergy
Age
- \<18 years of age
Other
- More than 48 hours since delivery at the time of randomization
- Unable or declined consent
Who the study is looking for
- ONE (or more) First Order Criterion:
- Known inherited thrombophilia diagnosed prior to enrolment, regardless of family history of VTE:
- Heterozygous factor V Leiden, or ii. Heterozygous prothrombin gene variant, or iii. Protein C deficiency, or iv. Protein S deficiency, and/or
- Antepartum immobilization for ≥7 days. Immobilization is defined as bed rest with 90% of waking hours spent in bed at any time during the antepartum period AND/OR
- TWO (or more) Second Order Criteria:
- Pre-pregnancy BMI ≥30 kg/m²
- Smoking in the current pregnancy or within 3 months prior to pregnancy
- Previous clinical history of superficial vein thrombosis
- Preeclampsia
- Current pregnancy ending in stillbirth (pregnancy loss \>20 weeks gestation)
- Unplanned cesarean delivery (unplanned = not a scheduled cesarean delivery)
- Small-for-gestational-age infant at time of delivery (\<3rd percentile adjusted for gestational age and sex)
- Peripartum or postpartum infection (symptoms/signs of infection and documented fever and laboratory evidence of infection with positive blood cultures or an elevated white blood cell count based on local laboratory cutoffs)
- Postpartum hemorrhage (≥1000 mL of blood loss, regardless of delivery mode)
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Association Hospitaliere De Bruxelles Et De Schaerbeek Centre Hospitalier Universitaire Brugmann Coordinator of this site? Confirm its status | Brussels | Belgium | Not yet recruiting |
| Foothills Medical Centre Coordinator of this site? Confirm its status | Calgary | Canada | Recruiting |
| The Ottawa Hospital - General Campus Coordinator of this site? Confirm its status | Ottawa | Canada | Not yet recruiting |
| Hvidovre Hospital Coordinator of this site? Confirm its status | Hvidovre | Denmark | Not yet recruiting |
| CHU de Nancy Coordinator of this site? Confirm its status | Nancy | France | Not yet recruiting |
| APHP - Hôpital Port Royal Coordinator of this site? Confirm its status | Paris | France | Not yet recruiting |
| Chu de Saint Etienne Coordinator of this site? Confirm its status | Saint-Etienne | France | Not yet recruiting |
| CHU de Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Not yet recruiting |
| Rotunda Hospital, RCSI Department of Obstetrics and Gynaecology Coordinator of this site? Confirm its status | Dublin | Ireland | Not yet recruiting |
| UCD Centre for Human Reproduction, The Coombe Hospital Coordinator of this site? Confirm its status | Dublin | Ireland | Not yet recruiting |
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Not yet recruiting |
| Medical University of Warsaw Coordinator of this site? Confirm its status | Warsaw | Poland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.